trending Market Intelligence /marketintelligence/en/news-insights/trending/sux1sklv6gq0oldxzkcuvg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

BeyondSpring appoints CFO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


BeyondSpring appoints CFO

New York's BeyondSpring Inc. appointed Edward Liu CFO.

Liu has more than a decade of senior banking experience, having served at J.P. Morgan and Jefferies. Prior to joining BeyondSpring, he served as partner and executive director at Epiphron Capital, an early investor in the company.

"His distinct blend of healthcare and in-depth financial expertise will be a key addition to the leadership team's collective experience as we advance toward our goal to submit New Drug Applications in China around year-end 2018/early 2019, and in the U.S. beginning in 2019," BeyondSpring CEO Lan Huang said in a statement.

BeyondSpring develops therapies for cancer using immuno-oncology.

BeyondSpring's lead asset, Plinabulin, is in a phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and two phase 2/3 clinical programs in the prevention of chemotherapy-induced neutropenia.